This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
POLIVY 140 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION — Description, Dosage, Side Effects | PillsCard
OTC
POLIVY 140 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
INN: POLIVY
Data updated: 2026-04-11
Available in:
🇩🇪🇬🇧🇪🇸
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
Roche Registration Gmbh
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
(ES)
Source
CIMA_ES
EUEMA:by INNUSDailyMed:Polatuzumab vedotin
AU:D
L01FX14(WHO)
AU:S4(Prescription only)CA:℞-only/ Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only)
1313206-42-6
8404
DB12240
none
KG6VO684Z6
D10761
Polatuzumab vedotin, sold under the brand namePolivy, is anantibody-drug conjugatemedication used for the treatment ofdiffuse large B-cell lymphoma(cancer).Polatuzumab is anantibodythat targetsCD79b, andvedotinis an agent that inhibits cell division by blocking the polymerisation oftubulin.
It was developed by theGenentechsubsidiary ofRoche.
The most common side effects include low levels of white blood cells (neutropenia), platelets (thrombocytopenia) and red blood cells (anemia); nerve damage (peripheral neuropathy); fatigue; diarrhea; fever; decreased appetite; and pneumonia.
Polatuzumab vedotin was approved for medical use in the United States in June 2019,in Australia in October 2019,in the European Union in January 2020,and in Canada in November 2020.
